Aaron's take on that, in layman's terms: Aaron5
Post# of 154118
(Total Views: 731)
Posted On: 07/25/2022 9:49:16 AM
Aaron's take on that, in layman's terms:
Aaron5 minutes ago
"The new 8K.
Apparently Cytodyn has pushed the 180 days deadline for the covenant in the surety agreement back until November 15th.
Most likely the arbitration has determined they won't have a resolution before that date. So no need to tie up funds for those months.
I theorized last week that the current price action was due to Welch making purchases due to the deadline for the covenant from the backstop. I was correct it appears. I simply didn't foresee the extension of the covenant deadline.
Welch currently owns more than 5% of Cytodyn. He has over 42 million shares. Welch has been with Cytodyn for 8 years I believe. And while he would certainly qualify for a 13D action, I note he didn't take part in that last year.
So his purchases and loyalty to Cytodyn speak volumes in his trust in the molecule and in current management.
I don't believe the IP is at risk at all. When the money (again, only if Amarex is owed a significant amount) is due, I am certain Cytodyn will secure the release of the IP indemnity so Welch doesn't end up owning the patents.
And clearly the patents aren't due to expire soon. We don't see Welch concerned about that, do we?"
Aaron5 minutes ago
"The new 8K.
Apparently Cytodyn has pushed the 180 days deadline for the covenant in the surety agreement back until November 15th.
Most likely the arbitration has determined they won't have a resolution before that date. So no need to tie up funds for those months.
I theorized last week that the current price action was due to Welch making purchases due to the deadline for the covenant from the backstop. I was correct it appears. I simply didn't foresee the extension of the covenant deadline.
Welch currently owns more than 5% of Cytodyn. He has over 42 million shares. Welch has been with Cytodyn for 8 years I believe. And while he would certainly qualify for a 13D action, I note he didn't take part in that last year.
So his purchases and loyalty to Cytodyn speak volumes in his trust in the molecule and in current management.
I don't believe the IP is at risk at all. When the money (again, only if Amarex is owed a significant amount) is due, I am certain Cytodyn will secure the release of the IP indemnity so Welch doesn't end up owning the patents.
And clearly the patents aren't due to expire soon. We don't see Welch concerned about that, do we?"
(5)
(0)